We narrowed to 600 results for: des.1

#198511-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#105547-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.EF1a.eGFP.WPRE.rBG (#105547). In addition to the viral particles, you will also receive purified pENN.AAV.EF1a.eGFP.WPRE.rBG plasmid DNA. EF1a-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 4, 2018

Academic Institutions and Nonprofits only

#83900-AAV5

Ready-to-use AAV5 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 25, 2023

Academic Institutions and Nonprofits only

#83900-AAV2

Ready-to-use AAV2 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 25, 2023

Academic Institutions and Nonprofits only

#83900-AAV8

Ready-to-use AAV8 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

May 22, 2023

Academic Institutions and Nonprofits only

#169256-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-hSyn-Soma-jGCaMP8s (#169256). In addition to the viral particles, you will also receive purified AAV-hSyn-Soma-jGCaMP8s plasmid DNA. hSyn-driven expression of soma-targeted calcium sensor GCaMP8s (more sensitive). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Sept. 27, 2023

Academic Institutions and Nonprofits only

#169257-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-hSyn-Soma-jGCaMP8m (#169257). In addition to the viral particles, you will also receive purified AAV-hSyn-Soma-jGCaMP8m plasmid DNA. Synapsin-driven expression of soma-targeted calcium sensor jGCaMP8m. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

March 18, 2024

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#174112-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#34910-AAV5

Ready-to-use AAV5 particles produced from paavCAG-pre-mGRASP-mCerulean (#34910). In addition to the viral particles, you will also receive purified paavCAG-pre-mGRASP-mCerulean plasmid DNA. CAG-driven expression of presynaptic mGRASP-mCerulean for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#239668-AAV8

Ready-to-use AAV8 particles produced from pAAV CaMKII:RiboL1-jGCaMP8m (#239668). In addition to the viral particles, you will also receive purified pAAV CaMKII:RiboL1-jGCaMP8m plasmid DNA. Neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8m under the CaMKII promoter. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#37825-AAV9-X1.1

Ready-to-use AAV9-X1.1 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the AAV9-X1.1 serotype, which permits efficient transduction of brain endothelial cells. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Sept. 27, 2024

Academic Institutions and Nonprofits only

#179529-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-4mtGCaMP6f-DIO (#179529). In addition to the viral particles, you will also receive purified pAAV-EF1a-4mtGCaMP6f-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#101064-AAV1

Ready-to-use AAV1 particles produced from pAAV_hsyn_NES-his-CaMPARI2-L398T-WPRE-SV40 (#101064). In addition to the viral particles, you will also receive purified pAAV_hsyn_NES-his-CaMPARI2-L398T-WPRE-SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator his-tagged CaMPARI2-L398T. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Moeyaert et al Nat Commun. 2018 Oct 25;9(1):4440. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#34912-AAV5

Ready-to-use AAV5 particles produced from paavCAG-post-mGRASP-2A-dTomato (#34912). In addition to the viral particles, you will also receive purified paavCAG-post-mGRASP-2A-dTomato plasmid DNA. CAG-driven expression of post-synaptic mGRASP-2A-dTomato for synaptic connectivity mapping. These AAV preparations are suitable purity for injection into animals.

Jinhyun Kim

Kim et al Nat Methods. 2011 Dec 4;9(1):96-102. doi

Aug. 7, 2025

Academic Institutions and Nonprofits only

#167574-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8m (#167574). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8m plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8m. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Dec. 18, 2024

Academic Institutions and Nonprofits only

#225708-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE (#225708). In addition to the viral particles, you will also receive purified pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE plasmid DNA. EF1a-driven, Cre-dependent soma-targeted expression of genetically encoded voltage indicator ASAP5. These AAV preparations are suitable purity for injection into animals.

Michael Lin

Hao et al Neuron. 2024 Sep 17:S0896-6273(24)00643-

Sept. 22, 2025

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#217676-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL (#217676). In addition to the viral particles, you will also receive purified pAAV-EF1α-DIO-GtACR2-P2A-Voltron2ST-W3SL plasmid DNA. EF1a-driven, Cre-dependent expression of GtACR2 and soma-targeted Voltron2 (ORCHID). These AAV preparations are suitable purity for injection into animals.

Joseph Raimondo

Selfe et al Nat Commun. 2024 Oct 16;15(1):8913. doi:

Feb. 9, 2026

Academic Institutions and Nonprofits only

#167572-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Ribo-jGCaMP8s (#167572). In addition to the viral particles, you will also receive purified AAV-hSyn-Ribo-jGCaMP8s plasmid DNA. Synapsin-driven neuronal expression of soma-targeted (RL-10, ribosomal tag) jGCaMP8s. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Dec. 18, 2024

Academic Institutions and Nonprofits only